Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases - results of a feasibility and case-control study - Abstract

PURPOSE: Androgen deprivation (ADT) represents the standard treatment for PCA with osseous metastases.

We explored the role of cytoreductive radical prostatectomy in PCA with low volume skeletal metastases in terms of a feasibility study.

MATERIAL AND METHODS: 23 patients with biopsy proven PCA, minimal osseous metastases (≤ 3 hot spots on bone scan), absence of visceral or extensive lymph node metastases and PSA decrease to < 1.0 ng/ml after neoadjuvant ADT were included in the feasibility study. 38 men with metastatic PCA who were treated by ADT without local therapy served as control group (group B). Surgery-related complications, time to castration resiatence, symptomatic-free, cancer-specific and overall survival were analyzed using descriptive statistical analysis.

RESULTS: Mean age was 61 (42-69) and 64 (47-83) years in group A and B, respectively, with similar patient characteristics in terms of initial PSA, biopsy Gleason score, clinical stage, extent of metastatic disease. The median follow-up was 34.5 (7-75) and 47 (28-96) months in group A and B, respectively. Median time to CRPC was 40 (9-65) and 29 (16-59) months in groups A and B, respectively (p=0.04)- Patients in group A experienced significantly better clinical PFS (38.6 versus 26.5 months, p=0.032) and cancer specific survival rate (95.6% versus 84.2%, p=0.043) whereas the overall survival was similar. 0% and 29% of men in group A and B, respectively, underwent palliative surgical procedures for locally progressing PCA.

CONCLUSIONS: CRP is feasible in well selected men with metastatic PCA who respond well to neoadjuvant ADT. These men have a long life expectancy and CRP reduces the risk of locally recurrent PCA and local complications. CRP might be a treatment option in the multimodality management of PCA with minimal osseous metastases.

Written by:
Heidenreich A, Pfister D, Porres D.   Are you the author?
Department of Urology, Uniklinik RWTH Aachen, Germany.  

Reference: J Urol. 2014 Sep 21. pii: S0022-5347(14)04486-3.
doi: 10.1016/j.juro.2014.09.089

PubMed Abstract
PMID: 25254935 Prostate Cancer Section


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.